{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T08:45:36Z","timestamp":1779353136553,"version":"3.51.4"},"reference-count":34,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T00:00:00Z","timestamp":1485216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Centre","doi-asserted-by":"publisher","award":["NCN\u20102012\/05\/D\/NZ5\/01846"],"award-info":[{"award-number":["NCN\u20102012\/05\/D\/NZ5\/01846"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:p><jats:italic>BRCA1\/2<\/jats:italic>\u2010associated breast cancers are sensitive to poly(ADPribose) polymerase (PARP) inhibitors and platinum compounds mainly due to their deficiency in DNA repair <jats:italic>via<\/jats:italic> homologous recombination (HR). However, approximately only 15% of triple\u2010negative breast cancers (TNBCs) are <jats:italic>BRCA1\/2<\/jats:italic>\u2010associated. TNBCs that exhibit BRCAness (a phenotype reflecting impaired HR in <jats:italic>BRCA1\/2<\/jats:italic>\u2010negative tumors) are also regarded sensitive to PARP inhibitors and platinum compounds. Thus, we hypothesized that hereditary <jats:italic>BRCA1\/2<\/jats:italic>\u2010negative TNBCs may exhibit BRCAness. To find a subset of hereditary <jats:italic>BRCA1\/2<\/jats:italic>\u2010negative TNBCs among 360 TNBCs, we first identified a group of 41 hereditary TNBCs by analyzing the family histories of the patients. Next, we tested this group for the presence of germline <jats:italic>BRCA1\/2<\/jats:italic> mutations, and finally, we compared the expression levels of 120 genes involved in HR and five other major mechanisms of DNA damage repair between <jats:italic>BRCA1\/2<\/jats:italic>\u2010associated and <jats:italic>BRCA1\/2<\/jats:italic>\u2010negative subgroups of hereditary TNBCs using real\u2010time PCR arrays. Approximately 73% of the hereditary TNBCs were <jats:italic>BRCA1\/2<\/jats:italic>\u2010associated and 27% were <jats:italic>BRCA1\/2<\/jats:italic>\u2010negative. The expression levels of the analyzed genes showed no significant differences between these two subgroups indicating the BRCAness of the <jats:italic>BRCA1\/2<\/jats:italic>\u2010negative hereditary TNBCs and thereby distinguishing a novel subset of TNBCs as a potential target for PARP inhibitors or platinum\u2010based therapy. The results show the significance of family history in selecting patients with TNBC for therapies directed at incompetent DNA repair (<jats:italic>e.g<\/jats:italic>., PARP inhibitors and\/or platinum\u2010based therapies) and indicate that a relatively simple strategy for broadening the target group for these modes of treatment is to identify patients with hereditary TNBCs.<\/jats:p>","DOI":"10.1002\/ijc.30570","type":"journal-article","created":{"date-parts":[[2016,12,10]],"date-time":"2016-12-10T23:20:14Z","timestamp":1481412014000},"page":"1545-1550","source":"Crossref","is-referenced-by-count":12,"title":["<i>BRCA1\/2<\/i>\u2010negative hereditary triple\u2010negative breast cancers exhibit BRCAness"],"prefix":"10.1002","volume":"140","author":[{"given":"Pawel","family":"Domagala","sequence":"first","affiliation":[{"name":"Department of Pathology Pomeranian Medical University Szczecin Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanta","family":"Hybiak","sequence":"additional","affiliation":[{"name":"Department of Pathology Pomeranian Medical University Szczecin Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cezary","family":"Cybulski","sequence":"additional","affiliation":[{"name":"Department of Genetics and Pathology International Hereditary Cancer Center, Pomeranian Medical University Szczecin Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Lubinski","sequence":"additional","affiliation":[{"name":"Department of Genetics and Pathology International Hereditary Cancer Center, Pomeranian Medical University Szczecin Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,1,24]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5306"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.66"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-010-0988-3"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.6231"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2014.07.004"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-3100-x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19970304)70:5<551::AID-IJC10>3.0.CO;2-G"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03445"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130393"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2015.04.011"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.0719"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11412"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2015.21"},{"key":"e_1_2_6_15_1","doi-asserted-by":"crossref","first-page":"viii13","DOI":"10.1093\/annonc\/mdt306","article-title":"BRCAness: a deeper insight into basal\u2010like breast tumors","volume":"24","author":"Summa S","year":"2013","journal-title":"Ann Oncol"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11900"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-013-0158-0"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603753"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/1897-4287-6-2-88"},{"key":"e_1_2_6_20_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Genetic\/Familial High\u2010Risk Assessment: Breast and Ovarian. National Comprehensive Cancer Network (ed 2.) 2016. Available at:http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp. (Accessed September 08 2016)."},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0140"},{"key":"e_1_2_6_22_1","first-page":"301","article-title":"The ups and downs of DNA repair biomarkers for PARP inhibitor therapies","volume":"1","author":"Wang X","year":"2011","journal-title":"Am J Cancer Res"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.352"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-2541"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2010.01.010"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2002-3-7-research0034"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/PDM.0b013e3181831320"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep21418"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-013-9246-y"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-09-0069"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.5719"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.144"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3655"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2014.03.019"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1269"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.30570","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.30570","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T14:59:45Z","timestamp":1695481185000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.30570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,24]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1002\/ijc.30570"],"URL":"https:\/\/doi.org\/10.1002\/ijc.30570","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,24]]}}}